Roche Antibody Cocktail launched at `59,750/dose

New Delhi, May 24: Drug majors Roche India and Cipla on Monday announced launch of Roche's Antibody Cocktail in India priced at Rs 59,750 per dose for the treatment of mild to moderate Covid19 in patients who are at high risk.

"The first batch of the Antibody Cocktail (Casirivimab and Imdevimab) is now available in India while a second batch will be made available by midJune. In total they can potentially benefit 2,00,000 patients as each of the

1,00,000 packs that will be available in India offers treatment for two patients," Cipla and Roche said in a joint statement.

Cipla will distribute the product, it added.

The price for each patient dose [a combined dose of

1,200 mg (600 mg of Casirivimab and 600 mg of Imdevimab)] will be Rs

59,750 inclusive of all taxes. The maximum retail price for the multi dose pack (each pack can treat two patients) is Rs 1,19,500, inclusive of all taxes

As per the statement, the drug will be available through leading hospitals and Covid treatment

The Central Drugs Standards Control Organisation had recently provided an emergency use authorisation (EUA) for the Antibody Cocktail (Casirivimab and Imdevimab) in India. It has also received a EUA in the US and several EU countries.

We are optimistic that the availability of Antibody Cocktail in India can help in minimising hospitalisation...play a key role in treatment of high risk patients before their condition worsens, said V. Simpson Emmanuel, MD and CEO, Roche Pharma India.

Umang Vohra, MD and Global CEO of Cipla said we look forward to leveraging our solid marketing and distribution strengths in India to provide broader, equitable access to this innovative treatment option in the country.

The cocktail is to be administered for the treatment of mild to moderate Covid in adults and children (above 12 years weighing at least 40 kg) who are confirmed to be infected with Sars-Cov2.